Guest Host: Jen Golbeck

The chief executive of a pharmaceutical company caused a public outcry when he acquired sole U.S. rights to distribute a lifesaving drug and raised the price by more than 5000 percent. But the issue goes well beyond one company and one former hedge fund manager. A number of companies have been quietly cornering the market on older, off-patent drugs–and hiking prices. We speak with a medical historian about the economics of drug pricing, and why “generic” doesn’t guarantee competition.


  • Jeremy Greene MD; Professor of Medicine and the History of Medicine, Johns Hopkins University School of Medicine; Author, “Generic: The Unbranding of Modern Medicine.”

Related Links

Topics + Tags


comments powered by Disqus
Most Recent Shows

Redressing Segregation In Maryland’s Public Higher Education

Thursday, Nov 16 2017The federal court judge who ruled that Maryland's public universities were unlawfully segregated rejected solutions proposed by the state's Higher Education Commission and a group representing a coalition of Maryland Historically Black Colleges and Universities for redressing that segregation. We get an update on the case.